Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
34,723,329
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
18,211,636
-
Shares change
-
+604,752
-
Total reported value, excl. options
-
$486,765,522
-
Value change
-
+$12,666,928
-
Put/Call ratio
-
70%
-
Number of buys
-
53
-
Number of sells
-
-36
-
Price
-
$26.73
Significant Holders of IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) as of Q1 2022
123 filings reported holding IGMS - IGM Biosciences, Inc. - Common Stock, par value $0.01 per share as of Q1 2022.
IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18,211,636 shares
of 34,723,329 outstanding shares and own 52% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (3,334,355 shares), BAKER BROS. ADVISORS LP (3,156,102 shares), PRICE T ROWE ASSOCIATES INC /MD/ (2,246,041 shares), Artal Group S.A. (2,000,000 shares), ALKEON CAPITAL MANAGEMENT LLC (1,034,035 shares), VANGUARD GROUP INC (830,077 shares), BlackRock Inc. (694,798 shares), UBS ASSET MANAGEMENT AMERICAS INC (560,711 shares), GOLDMAN SACHS GROUP INC (428,087 shares), and Woodline Partners LP (403,401 shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.